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Abstract
Background: At least 90% of human genes are alternatively spliced. Alternative splicing has an important function
regulating gene expression and miss-splicing can contribute to risk for human diseases, including Alzheimer’s
disease (AD).
Methods: We developed a splicing decision model as a molecular mechanism to identify functional exon skipping
events and genetic variation affecting alternative splicing on a genome-wide scale by integrating genomics,
transcriptomics, and neuroimaging data in a systems biology approach. In this study, we analyzed RNA-Seq
data of hippocampus brain tissue from Alzheimer’s disease (AD; n= 24) and cognitively normal elderly controls (CN;
n = 50) and identified three exon skipping events in two genes (RELN and NOS1) as significantly associated
with AD (corrected p-value < 0.05 and fold change > 1.5). Next, we identified single-nucleotide polymorphisms (SNPs)
affecting exon skipping events using the splicing decision model and then performed an association analysis of SNPs
potentially affecting three exon skipping events with a global cortical measure of amyloid-β deposition measured by
[18F] Florbetapir position emission tomography (PET) scan as an AD-related quantitative phenotype. A whole-brain
voxel-based analysis was also performed.
Results: Two exons in RELN and one exon in NOS1 showed significantly lower expression levels in the AD participants
compared to CN participants, suggesting that the exons tend to be skipped more in AD. We also showed the loss of
the core protein structure due to the skipped exons using the protein 3D structure analysis. The targeted SNP-based
association analysis identified one intronic SNP (rs362771) adjacent to the skipped exon 24 in RELN as significantly
associated with cortical amyloid-β levels (corrected p-value < 0.05). This SNP is within the splicing regulatory element, i.
e., intronic splicing enhancer. The minor allele of rs362771 conferred decreases in cortical amyloid-β levels in the right
temporal and bilateral parietal lobes.
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Conclusions: Our results suggest that exon skipping events and splicing-affecting SNPs in the human hippocampus
may contribute to AD pathogenesis. Integration of multiple omics and neuroimaging data provides insights into possible
mechanisms underlying AD pathophysiology through exon skipping and may help identify novel therapeutic targets.
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Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder pathologically characterized by an accu-
mulation of both toxic amyloid-β plaques and
neurofibrillary tau tangles in the brain [1]. Twin studies
as well as more recent large-scale genome-wide associ-
ation studies (GWAS) have demonstrated that genetic
susceptibility factors play an important role in the devel-
opment of the AD, although there is still a substantial
portion of missing heritability to be identified [2, 3]. In-
creasing evidence suggests that widespread transcrip-
tional changes accompany the onset and progression of
AD [4–8]. In particular, the aberration in the control of
gene expression by alternative splicing is implicated in
AD [9–12]. Previous whole transcriptome sequencing
analyses revealed gene expression and alternative spli-
cing changes in the AD-affected brain regions [4, 10–
12]. Several alternatively spliced AD candidate genes
such as CLU and CD33 were reported to be associated
with AD pathogenesis [13, 14]. Thus, it could provide
valuable information on the underlying pathology associ-
ated with the AD to identify other alternative spliced
genes and AD-associated single-nucleotide polymor-
phisms (SNPs) affecting splicing regulation.
Alternative splicing is the process by which a single
gene can produce multiple RNA isoforms through the
splicing in and out of different portions of the transcript.
Although it is an important mechanism for increasing
biological complexity through generating tissue-specific
transcript, miss-splicing can lead to different disease
states. For example, in humans, more than 90% of genes
are alternatively spliced [15] and generating 100, 000
proteins through different usage of exons (i.e. alternately
spliced exons) [16]. Furthermore, such transcripts or
certain exon skipping are expressed in the tissue- and
disease-specific manner. Especially more genes are alter-
natively spliced in the brain than other tissues [16], and
specific exons are brain-specially skipped or included in
AD-associated genes including APP [13, 16], PSEN1
[17], PSEN2 [17], APOE [16], and MAPT [18–20].
SRE is an ancillary cis-acting element as a part of the
splicing machinery that assists a spliceosome to correctly
recognize the exon-intron boundary by recruiting activa-
tor or repressor Trans-acting RNA-binding proteins
(RBP) [21]. There are four types of SREs, exonic splicing
enhancers (ESEs), exonic splicing silencers (ESSs), intronic
splicing enhancers (ISEs), and intronic splicing silencers
(ISSs). Mutation in any sites of SREs changes the binding
accuracy of spliceosome to the splice sites and potentially
result in the aberrant exon skipping events producing
disease-causing proteins. Furthermore, 15% of disease-
causing mutation is estimated to be associated with spli-
cing including SREs and splice sites [22–24], and we have
previously demonstrated that alternative splicing is useful
for identifying disease-associated variation in the human
genome [25, 26]. It remains difficult to identify novel
genes and molecular mechanisms associated with splicing
that underlie AD pathological hallmarks due to the nature
of studying the brain and neuropathological traits.
This study explores how transcriptomics, genomics
and neuroimaging endo-phenotypes can be leveraged as
a means to clarify our understanding of the genetic
architecture of AD. Using RNA-Seq data from cogni-
tively normal elderly controls and AD-affected human
hippocampal tissues, alternative splicing isoforms were
evaluated by measuring exon skipping. A computational
pipeline to identify exon skipping events using RNA-Seq
data and a splicing decision model to identify actionable
loci among common SNPs for gene regulation were ap-
plied in this study to gain insights into the functionality
of the variations and emphasized their importance for
the AD pathology [27]. We identified SNPs affecting
exon skipping by analyzing sequence-driven alternative
splicing models and by scanning the genome for the re-
gions with putative splicing regulatory elements (SREs)
motifs [26, 27]. Aberrant alternative splicing sites were
detected that associate with the AD using SNPs within
regions affecting the exon skipping as associated with
AD-related neuroimaging biomarkers, a global cortical
measure of amyloid-β deposition measured by [18F] Flor-
betapir position emission tomography (PET) scans.
These results provide a new link between alternative
splicing changes and AD.
Methods
Study sample and RNA-sequencing data analysis
RNA-Seq data (bam files) were downloaded from the
Allen Brain Atlas (http://human.brain-map.org/). RNA
was isolated from the hippocampus tissue of brains of
AD patients (AD; n = 24) and non-AD elderly controls
(CN; n = 50) from the Adult Changes in Thought (ACT)
study. The ACT study is a longitudinal population-based
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prospective cohort study of brain aging and incident
dementia in the Seattle metropolitan area, as de-
scribed in detail in previous studies [28, 29]. RNA se-
quencing was performed using an Illumina HiSeq
2500 with v4 chemistry, producing a minimum of 30
M 50 bp paired-end clusters per sample. Raw read
files (bam files) were aligned to the GRCh38 reference
genome, as described in detail (http://aging.brain-ma-
p.org/). The average reads of all individual partici-
pants (n = 74) were 55,015,989.
Identification of exon skipping events
A bioinformatics splicing decision model based on our
previous study [27] was implemented to identify exon
skipping events and genetic variation affecting exon
skipping using RNA-Seq data on a genome-wide scale in
the human hippocampus (Fig. 1). First, to estimate the
normalized usage for each exon, total reads for each
exon were counted from RNA-seq data (bam files with
the mapped reads) using HTSeq [30, 31] and there were
only exon reads, but no junction reads. Junction reads
are crucial information to know which exon structure is
changed. However, as we obtained the exon reads from
the bam files, we run DEXSeq to measure exon expres-
sion level that basically uses exon reads only [31]. Next,
expressed exons (exon skipping events) between AD and
CN were identified using a generalized linear regression
model in DEXSeq. The statistical cutoff as a significantly
differentially expressed exon (exon skipping) was false
discovery rate (FDR)-corrected p-value < 0.05 and fold
change > 1.5, which was calculated with p.adjust func-
tion in R, i.e., correction for multiple comparisons was
performed using the FDR-based multiple comparison
adjustment with the Benjamini-Hochberg procedure at a
0.05 level of significance.
Identification of SNPs in splicing regulatory elements
associated with exon skipping events
We have developed a splicing decision model for identi-
fying SNPs affecting splicing regulatory elements (SREs)
with exon skipping by using alignment information for
four alternative splicing datasets from the UCSC genome
browser: mRNAs from GenBank [32], Ensembl Gene
Predictions [33], AceView Gene Models [34], and UCSC
known genes [35] and a set of predicted hexameric SRE
motifs, as described in detail in previous publications
[26, 27]. We searched for all potential SRE sites that are
perfectly matched with any of these hexamers in intra-
genic regions (exons and introns). Our study included
three types of SREs available for this time, ESE, ESS, and
ISE according to its location and function without ISS as
the data of ISS hexameric sequences are not available.
We then compiled genotype data and SRE regions with
skipping of the adjacent exon to intron or skipping of
the exon embedding SRE region, which is a definition of
splicing decision model that computationally predict the
Fig. 1 Computational pipeline for identifying AD-associated exon skipping events and SNPs affecting exon skipping
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loss-of-function of SRE by SNP. Using the splicing deci-
sion model, we identified SNPs within SREs associated
with exon skipping events.
Functional annotation of differentially expressed exons
The impact of exon skipping events on protein structure
and function was evaluated in silico. The skipped exons
are translated into a functional domain, lead to out of
frame through a frameshift, and change their corre-
sponding protein structure using UniProt web browser
and RaptorX [36].
Neuroimaging and genotyping analysis
[18F] Florbetapir PET scans downloaded from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
were pre-processed as described [37]. [18F] Florbeta-
pir PET scans were intensity normalized by the
whole cerebellum. The normalization yielded stan-
dardized uptake value ratio (SUVR) images. The on-
going ADNI study was launched in 2003 to test
whether serial magnetic resonance imaging (MRI),
PET, other biological markers, and clinical and
neuropsychological assessment could be combined to
measure the progression of MCI (mild cognitive im-
pairment) and early AD, as published previously [38,
39] and found at www.adni-info.org. Genotyping for
ADNI was performed using three different Illumina
genotyping platforms. We imputed un-genotyped
SNPs separately in each platform using MACH and
the HRC (Haplotype Reference Consortium) data as
a reference panel after standard sample and SNP
quality control procedures and selection of only
non-Hispanic Caucasian participants [40].
Association of SNPs affecting exon skipping with AD-
related neuroimaging endophenotype
First, an association analysis was performed for SNPs
that potentially affect identified exon skipping events
with a global cortical measure of amyloid-β deposition
as measured by PET scans in an AD-related quantitative
phenotype. The global cortical amyloid-β level was cal-
culated as a mean regional SUVR value extracted for the
frontal, parietal, temporal, limbic, and occipital lobes
using the MarsBaR toolbox implemented in the Statis-
tical Parametric Mapping 8 (SPM8) software (http://
www.fil.ion.ucl.ac.uk/spm/software/spm8/) [41]. Also, a
detailed whole brain-based neuroimaging analysis was
performed using multivariate models for amyloid-β
levels on voxel-by-voxel bases. Age at baseline, sex, and
years of education were used as covariates for the associ-
ation test. Correction for multiple comparisons was per-
formed using false discovery rate (FDR) correction
method at a 0.05 level of significance.
Results
This study analyzed RNA-Seq data of hippocampus
brain tissues from 74 participants from the ACT
study. Participants were diagnosed as cognitively nor-
mal elder controls (CN) or AD patients. As shown in
Table 1, there were 24 AD and 50 CN participants,
and the mean Braak stages of AD and CN were 4.4
and 2.78, respectively.
Differentially expressed exons in AD hippocampus tissue
Using the computational pipeline described in Fig. 1,
normalized expression levels were calculated for each
exon in a genome-wide manner, and a generalized linear
regression model was used to identify AD-associated
exon skipping events. After adjusting for multiple com-
parisons using the FDR method, we identified three exon
skipping events in two genes, RELN and NOS1, as
significantly associated with the AD (FDR-corrected
p-value < 0.05 and fold change > 1.5). Two exons in
RELN, exons 24 and 37, showed significantly lower ex-
pression levels in AD patients compared to CN partici-
pants, suggesting that the exons tend to be skipped
more in the AD (Fig. 2a). The exon 24 was predicted to
encode a hEGF domain region (PF00008, Fig. 2b). Fur-
thermore, for AD participants, we investigated whether
the Braak stage is associated with the exon skipping
event. In 24 AD participants, 19 were in the Braak stages
4, 5 and 6. Among the 19 AD participants in higher
Braak stages, 15 showed significantly lower expression
levels of the exon 24 compared to the other 4 AD partic-
ipants (one-way chi-squared test, p-value = 0.01), sug-
gesting that the exon tends to be skipped more in higher
Braak stages of AD participants. In NOS1, exon 23 had
lower expression levels in AD patients compared to CN
participants (Fig. 3a) and was a part of the NO_synthase
domain (PF02898, Fig. 3b). Our results suggest that
these exon skipping events may affect the function of
the corresponding protein products.
Table 1 Demographic characteristics of 74 study samples
# of sample Male/Female Age
[min-max]
Education
[min-max]
Braak stage
AD 24 11/13 91 (7.2) [78–100+] 14.4 (3.25) [6–21] 4.4 (1.70) [0–6]
CN 50 30/20 89 (6.9) [78–100+] 14.7 (3.07) [8–21] 2.76 (1.49) [0–6]
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Prediction of the effect of the identified exon skipping
events on protein
To characterize the potential impact of the variants on the
protein, each variant was analyzed using UniProt web
browser and RaptorX. All of three skipped exons in RELN
and NOS1 resulted in producing a coding sequence which
is out-of-frame, potentially generating an undesired pro-
tein product. As presented in Fig. 4, the first AD-associ-
ated exon skipping (exon 24) in RELN showed lower
expression levels of the exon in AD compared to CN par-
ticipants (Fig. 4b; FDR-corrected p-value = 0.034, fold
change = 1.51). The adjacent exon 23 and 25 showed simi-
lar levels of difference but not significant (FDR = 0.154 for
both exons, fold change = 1.39 and 1.37, respectively). The
transcript (transcript1) retaining the exon 24, which en-
codes the hEGF, likely results in a functional version of
the RELN gene, while the transcript which lacks exon 24
will lose the hEGF domain and thus produce the trun-
cated protein product due to the out-of-frame of the exon
length (Fig. 4a). Structural analysis of the truncated ver-
sion of the protein suggests that exon skipping may be im-
plicated in functional changes of RELN in the AD (Fig.
4c). The other exon (exon 37) in RELN is presented in
Additional file 1: Figure S1. Additionally, exon 23 was
identified as being skipped in NOS1 (Fig. 5a). AD partici-
pants had significantly lower expression levels of the exon
compared to CN (Fig. 5b; FDR corrected p-value = 0.043,
fold change = 1.90). The transcript (transcript1) retaining
the exon 23, which encodes a part of the NO_synthase,
can be translated into the protein with normal functions
of NOS1. In contrast, the transcript with the skipping of
exon 23 may not only lose the NO_synthase domain but
also produce the truncated protein due to the out-of-
frame of the exon length. We also showed the partial loss
of the protein structure due to the skipped exon using the
protein 3D structure analysis (Fig. 5c).
Association of SNPs affecting exon skipping with AD-
related neuroimaging phenotypes
Next, we performed an association analysis of SNPs affect-
ing exon skipping events with a global cortical measure of
amyloid-β deposition as an AD-related quantitative
phenotype. Using the splicing decision model, we first
identified 46 and 11 SNPs in RELN and NOS1, respect-
ively, potentially affecting the identified three exon skip-
ping events (MAF > 1%) from HRC-based imputed ADNI
GWAS data. We identified one SNP (rs362771) in intron
adjacent to the skipped exon 24 in RELN as significantly
A
B
Fig. 2 Two AD-associated exon skipping events in RELN. a Comparison of the expression levels of each exon between AD and CN participants,
indicating two significant exon skipping events (exons 24 and 37) in the AD. b Exon structure and the hEGF domain encoded by the skipped
exons (UCSC genome browser)
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associated with cortical amyloid-β levels (Fig. 6a;
permutation-based corrected p-value < 0.05). Further-
more, we performed an unbiased whole-brain-based im-
aging association analysis using age, sex, years of
education as covariates to assess the effect of rs362771 on
whole-brain amyloid-β deposition and identified signifi-
cant associations after adjustment for multiple compari-
sons using cluster-wide FDR procedure. The minor allele
of rs362771 conferred decreases in cortical amyloid-β
levels in the right temporal and bilateral parietal lobes
(Fig. 6b). As shown in Fig. 4a, we found that the SNP
(rs362771) is located within the ISE site (5th site of hex-
ametric sequence CCTTCC), suggesting that the SNP may
affect the exon skipping and the skipped exon may be as-
sociated with AD pathogenesis.
Discussion
Here we developed a computational pipeline for the
identification of exon skipping and a splicing decision
model for the identification of SNPs affecting exon skip-
ping. Altered expression patterns (exon skipping events)
within two distinct exon regions of RELN and NOS1 in
the human hippocampus affected by Alzheimer’s disease
(AD) were identified. Interestingly, expression levels of
identified alternatively spliced exons are decreased in the
AD and the minor allele of one SNP in RELN potentially
affecting exon skipping negatively correlate with a glo-
bal cortical amyloid-β burden. Our results indicate that
essential exon regions for the RELN and NOS1 genes
are alternatively spliced in the AD hippocampus com-
pared to cognitively normal elderly controls. It was pre-
viously reported that RELN delays amyloid-β fibril
formation and rescues cognitive deficits in an AD
model [42]. Two major neuropathological hallmarks of
the AD are the accumulation of toxic levels of
amyloid-β molecules and hyper-phosphorylated tau
protein that leads to neurofibrillary tangles. Although it
was known that RELN and NOS1 were associated with
neurologically related traits, the methodology presented
here suggests new possible mechanisms by which they
may influence AD pathology [43–45].
RELN is an extracellular matrix glycoprotein that plays a
number of important roles in the central nervous system
(CNS) and its dysfunction is associated with AD [46–48].
Many studies have found associations between genetic vari-
ation in RELN and neurological traits, often using
case-control study design [49]. Characterization of these
genetic associations is important however, it lacks mechan-
istic insight that can be provided with interrogating specific
regions of the gene, or incorporating other molecular infor-
mation, such as gene expression. By utilizing a neuroimag-
ing endophenotype, along with transcriptomic information
A
B
Fig. 3 One AD-associated exon skipping event in NOS1. a Comparison of the expression levels of each exon between AD and CN participants,
indicating a significant exon skipping event (exon 23) in the AD. b Exon structure and the NO_synthase domain encoded by the skipped exon
(UCSC genome browser)
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in relation to alternative splicing, we identified differential
expression levels among exons in RELN. The function of
the RELN protein is to help mediate cell migration during
brain development by activating a signaling pathway
through binding of cell surface proteins [46, 50]. These
pathways mediate the process of tau phosphorylation and a
reduction of RELN expression can significantly accelerate
amyloid-β deposition in transgenic AD mice [48]. Thus, dif-
ferential exonic usage with respect to the AD may produce
an isoform of RELN protein that potentially accelerates
amyloid-β deposition and/or mis-regulation of tau phos-
phorylation, both leading to AD-related phenotypes. Spe-
cific exonic expression appears to play an important role.
Thus, understanding the role of exon skipping may lead to
more consistent conclusions with respect to the role of
RELN and other proteins [46].
NOS1, the other gene identified in this work, has also
been of significant interest in relation to heart and neur-
onal function since nitric oxide (NO) is an important
signaling molecule that is produced by NO-producing
enzymes, such as NOS1 [51]. NOS can produce signifi-
cant amounts of reactive oxygen species (ROS) that can
lead to damaged proteins. Therefore, mis-splicing of
NOS1 could lead to increased ROS, and thus increased
protein mis-folding and aggregation associated with
neurodegenerative diseases (i.e. AD). Both increased
and decreased expression of NOS1 have been associ-
ated with a cognitive disruption in relation to the AD
[52]. Therefore, it will be interesting to characterize
how the expression of different isoforms and exons
contributes to the spectrum of phenotypes related to
AD in future work.
Although both genes had previous connections with
neuronal development and splicing [46, 51], this study
makes a novel association between alternative splicing
and AD with respect to NOS1 and RELN. Since both
RELN and NOS1 could exacerbate different mechanisms
by which AD arises, it would be interesting for future
work to investigate the co-occurrence of variants in
these genes and how it impacts neurological function.
While many advantages of the methodology employed
here have been described in detail, it is also valuable to
point out some limitations to avoid over-interpretation
and reflect on what improvements need to be addressed
in future work.
For instance, our sample size was moderate for this
study with respect to the expression analysis. Thus, we
may have missed some genes with alternative splicing
A
B C
Fig. 4 Functional impact of the AD-associated exon skipping event (exon 24) in RELN. a Schema of the potential functional implication of exon
skipping and splicing-associated SNP. b Normalized expression levels for exon 24 between AD and CN participants. c Structure alignment of the
pair of transcript1 retaining exon 24 (green) and transcript 2 with the exon skipping (red)
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in SRE SNPs associated with AD due to limited detec-
tion power. Previous work has suggested sex differences
in AD [47]. The other limitation by the original dataset
we used for exon expression quantification is that junc-
tion reads were excluded in the downloaded aligned
bam file. As junction reads are important resources for
estimating more accurate exon skipping events,
inclusion of the junction reads may improve the power
of our splicing decision model to detect differentially
expressed exons in AD. Additionally, it is necessary for
follow-up studies to test the function of exon skipping
events experimentally as well as to investigate the epi-
genetic changes influencing the splicing decision – es-
pecially association of DNA methylation status in
A B
Fig. 6 Regional effects (a; global cortical amyloid-β load) and voxel-wide association (b) of rs362771 in RELN affecting exon skipping with
amyloid-β deposition
A
B C
Fig. 5 Functional impact of the AD-associated exon skipping event (exon 23) in NOS1. a Skipping of exon 23. b Normalized expression levels for
exon 23 between AD and CN participants. c Structure alignment of the pair of transcript1 retaining exon 23 (green) and transcript 2 with the
exon skipping (red)
Han et al. BMC Medical Genomics 2019, 12(Suppl 1):13 Page 58 of 189
intragenic regions (exons and introns) [53–55]. Finally,
here we only explored AD, but the methods applied
here could be employed to understand the complex
gene-trait relationship among other neurological dis-
eases. In summary, through our integrative analysis of
RNA-Seq, genomics, and neuroimaging data, the RELN
and NOS1 genes were identified as having differential
exon usages with respect to the AD. This work also
suggests applying an imaging genetics approach, along
with utilizing SRE variants, will help shed light on pre-
viously unidentified gene-trait relationships.
Our study was not able to recapitulate a statistically sig-
nificant exon skipping or spliced isoforms in any of the
historical genes (i.e., including APP [13, 16], PSEN1 [17],
PSEN2 [17], APOE [16], and MAPT [18–20]). However
we observed there were the marginal signals of ten exons
in those genes at the unadjusted p-value < 0.05 and fold
changes between − 1.5 and 1.2, which might be due to the
following reasons, 1) alternative splicing events occur in
the tissue- and cell type- specific manner and are even
more specific to brain regions [15, 16, 56, 57], 2) our study
analyzed the RNA-Seq data from the hippocampus re-
gions whereas the known alternative splicing events in the
historical genes were found in the whole brain or cerebral
cortex region, and 3) as mentioned above, we might miss
a signal of those genes under the lack of detection power
(AD = 24 and non-AD elderly controls = 50).
Conclusion
In conclusion, this study provides evidence that our novel
approach can identify significant exon skipping events and
genetic variation potentially affecting exon skipping in
Alzheimer’s disease. Between RELN and NOS1, three
exons are altered in their expressions in the human hippo-
campus affected by Alzheimer’s disease. It also suggests
that the functional relationship between exon skipping
and protein structures for RELN and NOS1 may be altered
in AD pathology. Further studies are needed to better
understand the functional role that identified exon skip-
ping and SNPs affecting exon skipping play in AD patho-
physiology. Integration of multiple omics and neuro
imaging data in a systems biology approach will provide
valuable insights into a possible mechanism underlying
AD pathology through exon skipping, thus potentially
helping identify novel therapeutic targets.
Additional file
Additional file 1: Figure S1. Functional impact of the AD-associated
exon skipping event (exon 37) in RELN. (A) Schema of the potential functional
implication of exon skipping and splicing-associated SNP. (B) Normalized
expression levels for exon 37 between AD and CN participants. (C) Structure
alignment of the pair of transcript1 retaining exon 37 (green) and transcript 2
with the exon skipping (red). (PDF 58 kb)
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